Reportlinker Adds Global Anti-Infectives Industry

NEW YORK, March 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Anti-Infectives Industry

http://www.reportlinker.com/p0181107/Global-Anti-Infectives-Industry.html

This report analyzes the worldwide markets for Anti-Infectives in US$ Million. The report provides separate comprehensive analytics for US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. The report profiles 77 companies including many key and niche players worldwide such as Abbott Laboratories, Alcon Pharmaceuticals Ltd., Astellas Pharma, Inc., AstraZeneca PLC , Bayer HealthCare AG , Bristol-Myers Squibb Co., Boehringer Ingelheim, Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, . F. Hoffmann-La Roche, Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi-Aventis SA, and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ANTI-INFECTIVES MCP-6156

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW & DYNAMICS II-1

Introduction II-1

Anti-Infective Drugs - Mechanism of Action II-1

Increasing Drug Resistance - A Major Challenge to Reckon With II-1

Antibacterial Resistance Costs High II-1

Novel Approaches to Combat Drug-Resistant Strains II-2

Combination Therapy II-2

New Approach to Directly Target Illness Rather than Infection II-2

Antivirals Directed at Human Targets II-2

Immunomodulation II-2

Antivirulence II-2

Select Companies Involved in Anti-Virulence Drug Research II-3

Pipeline Analysis of Anti-Infectives by Therapeutic Class II-3

Table 1: Anti-Infectives Pipeline by Therapeutic Class and

Development Stage:(includes corresponding Graph/Chart) II-3

Injectables Gain Traction II-4

Market Outlook II-4

Anti-Bacterials Drive Global Anti-Infectives Market II-4

Table 2: World Market for Anti-Infectives (2008): Percentage

Share Breakdown of Value Sales by Therapeutic Class -

Anti-Bacterials, Anti-Virals, Anti-Fungals, and Others

(includes corresponding Graph/Chart) II-5

Anti-Virals - A Significant Market II-5

Original Brands Leads the Supreme II-5

Table 3: Global Market for Anti-Infectives by Licensing

Status (2006-07): Percentage Share Breakdown of Value Sales

for Branded, Licensed Brands, Unbranded Drugs, and Other

Drugs (includes corresponding Graph/Chart) II-5

United States - The Largest Anti-infectives Market Globally II-6

Table 4: World Market for Anti-Infectives by Geographic

Region (2010): Percentage Share Breakdown for US, Japan,

Europe, and Rest of World (includes corresponding

Graph/Chart) II-6

Table 5: World Market for Anti-Infectives: Breakdown of

Select Geographic Regions/Country by Value Growth Potential

for the Period 2006-2015 (includes corresponding

Graph/Chart) II-6

Europe - The Second Leading Worldwide Market for Anti-Infectives II-6

Competitive Landscape II-7

Table 6: Worldwide Anti-Infectives Market by Leading Players

(2007): Percentage Share Breakdown of Value Sales for Glaxo

SmithKline, Merck, Pfizer, Novartis, Gilead Sciences, Abbott,

Wyeth, Sanofi-Aventis, Bristol-Myers Squibb, Johnson &

Johnson (includes corresponding Graph/Chart) II-7

Table 7: Leading Anti-Infective Companies Worldwide and their

Brands: Value Sales for the year 2008 (includes corresponding

Graph/Chart) II-8

GlaxoSmithKline Portfolio of Anti-Infectives - Breakdown by

Therapeutic Class II-9

2. ANTI-BACTERIALS MARKET II-10

Market Estimates and Forecasts II-10

Market Analysis by Drug Class II-10

Table 8: Worldwide Market for Anti-Bacterials by Major Drug

Class (2008): Percentage Share Breakdown for Cephalosporins,

Macrolides, Fluoroquinolones, Penicillins, and Others

(includes corresponding Graph/Chart) II-10

Market Analysis by Region II-10

Competition in Anti-Bacterials Market II-11

Table 9: World Anti-Bacterials Market (2008): Break-Up of

Value Sales (US$ Billion) for Leading Drugs (includes

corresponding Graph/Chart) II-11

Global Market Outlook II-12

Antibacterial Resistance - A Key Growth Dampener II-12

Antibiotic-Resistant Bacteria by Type II-12

Bacterial Resistance to Most Commonly Used Antibacterial Drug

Class: Incidence Level in Select Countries II-12

Generic Competition Intensifies II-13

Patent Expiries Commoditize Antibiotics II-13

Patent Expiries of Major Anti-Bacterial Drugs II-13

R&D Initiatives Imperative for Developing Novel Drugs to

Combat Drug-Resistant Strains II-14

Hospital Market for Gram-Positive Antibacterials to Witness

Encouraging Gains II-14

Anti-MRSA Antibiotics Find Their Way II-14

What are Anti-bacterials? II-15

Taxonomy of Anti-bacterials II-15

Classification of Anti-bacterials based on Mechanism of Action II-16

Antibacterial Drug Classes II-16

Penicillin II-16

Cephalosporins II-16

Side Effects II-17

Fluroquinolones II-17

Side Effects II-17

Tetracyclines II-17

Treatment II-17

Side Effects II-18

Macrolides II-18

Treatment II-18

Side Effects II-18

Others II-18

Classification based on the Process of Suppressing or Killing

Bacteria II-18

Bactericidal or Bacteria Destroying Drugs II-19

Bacteriostatic Drugs II-19

Bacterial Spectrum II-19

Use of Antibacterial Drugs: An Overview II-19

Phage Therapy, a Promising Approach for Bacterial Infections II-19

How Does Phage Therapy Works? II-20

Treatment and Application of Phase Therapy II-20

Phages for Antibiotic-Resistant Bacteria II-20

Companies Involved in Phage Therapy Research II-21

3. ANTI-VIRALS MARKET II-22

Market Estimates and Forecasts II-22

Five Major Anti-Virals Dominate the Antivirals Market II-22

Players Active in Anti-Virals Market II-22

Table 10: Major Anti-Viral Drugs of GSK and Bristol-Myers

Squibb: Annual Sales for the year 2008 (includes

corresponding Graph/Chart) II-23

Market Leaders In 2008: A Review II-23

Table 11: World Anti-Virals Market (2008): Break-Up of Value

Sales (US$ Billion) For Leading Drugs (includes

corresponding Graph/Chart) II-24

Key Trends and Issues II-24

Preventative Antivirals Gain Significance II-24

Table 12: Global Market for Anti-Virals (2007): Percentage

Share Breakdown by Category - Antiviral Therapeutics,

Vaccines, Monoclonal Antibodies, and Others (includes

corresponding Graph/Chart) II-25

R&D Initiatives Abound in Antivirals Market II-25

Companies Involved in Late-Stage Development of Anti-virals II-25

Companies Involved in Phase II Clinical Studies of Anti-virals II-26

Companies Involved in Phase I Clinical Studies of Anti-virals II-26

Select Companies in Pre-clinical Development Phase of Anti-

virals II-27

Development of Direct Targeted Antiviral Therapies II-27

New Novel Anti-Viral Peptides II-27

siRNA Shows Antiviral Potential II-27

Combination Drug Therapy Gains Popularity II-28

Microbiocides, a New Way to Fight STD and HIV Infections II-28

What are Anti-Virals? II-29

Emergence of Antivirals II-29

Types of Antivirals II-29

Entry Blockers II-29

Drugs in the Market II-30

Viral Component Replication Blockers II-30

Viral Component Assimilation Blockers II-30

Antisense Molecules II-30

Synthetic Ribozymes II-30

Protease Inhibitors II-31

Blockers for Release of Completed Viruses from the Host Cell II-31

Other Types of Antivirals II-31

Interferons II-31

Synthetic Monoclonal Antibodies II-31

Major Viral Infections & Related Drugs II-32

Human Immunodeficiency Virus (HIV) II-32

HIV Treatment - The Largest in Anti-Virals Sector II-32

Major Anti-HIV/AIDS Drugs by Category II-32

Nucleoside Reverse Transcriptase Inhibitors (NRTIs) II-33

Major Nucleoside Reverse Transcriptase Inhibitors (NRTIs): II-33

Epivir (Lamivudine) II-33

Retrovir (Zidovudine)* II-33

Combivir (Epivir+Retrovir) II-33

Videx (Didanosine) II-34

Zerit (Stavudine) II-34

Hivid (Zalcitabine) II-34

Protease Inhibitors (PIs) II-34

Major Protease Inhibitors: II-34

Norvir (Ritonavir) II-34

Kaletra (Lopinavir+Ritonavir) II-35

Invirase (Saquinavir) II-35

Fosamprenavir II-35

Integrase Inhibitors (IIs) II-35

ISENTRESS II-35

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) II-35

Entry Blockers II-35

Fusion Inhibitors II-36

Fuzeon (Enfuvirtide) II-36

Antiviral siRNAs II-36

Drugs for HIV Infected Patients in Advanced Stage II-36

Combination Therapies For HIV Infected Patients II-36

Hepatitis Infection II-36

Acute and Chronic Hepatitis Infections II-37

Treatment Regimen for Hepatitis Infection II-37

Interferons II-37

Standard Interferons II-37

Pegylated Interferons II-38

Ribavirin II-38

Types of Hepatitis Infection based on Strains II-38

Hepatitis A Virus (HAV) Infection II-38

Hepatitis B Virus (HBV) Infection II-39

Treatment for Chronic HBV Infection II-39

Vaccines Dominate the Category II-39

Antiviral Drugs for Chronic HBV Infection II-39

Major Anti-HBV Drugs: II-40

Hepatitis C Virus (HCV) Infection II-40

Treatment for Chronic Hepatitis C Infection II-40

Some Alternative Treatments II-41

Drugs in Pipeline: II-41

Hepatitis C - Drugs in Pipeline As on March 2008 II-41

Hepatitis D Virus (HDV) Infection II-41

Hepatitis E Virus (HEV) Infection II-42

Herpes Simplex Virus (HSV) Infection II-42

Treatment for HSV Infection II-42

Major HSV Drugs Worldwide and their Patent Expiries II-43

Antivirals for HSV Infection II-43

Select HSV Infection Drugs II-43

Zovirax (Aciclovir) II-43

Famvir (Famciclovir) II-43

Foscavir (Foscarnet) II-44

Valtrex (Valaciclovir) II-44

Vectavir/Denavir (Penciclovir) II-44

Abreva (Docosanol) II-44

Ophthalmic Viral Infections & Related Drugs II-44

Cytovene (Ganciclovir) II-44

Vistide (Cidofovir) II-44

Foscavir (Foscarnet) II-44

Human Papilloma Virus (HPV) II-45

Treatment for HPV Infection II-45

Respiratory Viruses Infections II-45

Influenza Virus II-45

Treatment for Influenza II-45

Major Influenza Drugs Profile II-46

Symmetrel® (Amantadine) II-46

Flumadine (Rimantadine) II-46

Tamiflu (Oseltamivir) II-46

Relenza (Zanamivir) II-46

Respiratory Syncytial Virus (RSV) Infection II-46

Treatment for RSV and other Respiratory Viral Infections II-46

Other Types of Viral Diseases II-46

Treatment for Other Viral Diseases II-47

4. ANTI-FUNGALS MARKET II-48

Anti-Fungals Market - A Quick Review II-48

Current and Future Analysis II-48

Anti-fungals: An Introduction II-48

Classification of Anti-Fungal Drugs by Class II-48

Allylamines II-49

Select Systemic and Topical Anti-Fungal Drugs Classified

under Allylamines Group II-49

Azoles II-49

Select Systemic and Topical Anti-Fungal Drugs Classified

under Azoles Group II-49

Polyene Macrolides II-50

Select Systemic and Topical Anti-Fungal Drugs Classified

under Polyene Macrolides Group II-50

Others II-50

Other Systemic and Topical Anti-Fungal Drugs II-50

Fungal Infections & Treatment II-50

Aspergillosis - Disease & Symptoms II-50

General Syndromes of Aspergillosis & Treatment Options II-51

Pulmonary Aspergillosis II-51

Aspergilloma II-51

Invasive Aspergillosis II-51

Select Drugs Used for the Treatment of Invasive Aspergillosis II-52

Blastomycosis - Disease & Symptoms II-52

Blastomycosis Treatment: Azoles the Preferred Choice II-52

Select Drugs or Medications Used For Blastomycosis Fungal

Infection Treatment II-53

Candidiasis - Disease & Symptoms II-53

General Syndromes of Candidiasis & Treatment Options II-53

Mucocutaneous Candidiasis II-53

Treatment Options II-54

Select Drugs or Medications Used for the Treatment of

Cutaneous Candidiasis II-55

Invasive Candidiasis II-55

Treatment Options II-56

Cryptococcosis & Clinical Syndromes II-56

Treatment of Cryptococcosis II-56

Select Drugs Used for the Treatment of Cryptococcosis II-57

Histoplasmosis - Disease and Symptoms II-57

Treatment Options for Histoplasmosis II-57

Select Drugs Used for the Treatment of Histoplasmosis II-58

5. AN OVERVIEW OF VACCINES MARKET II-59

Introduction II-59

Serum Institute of India Ltd. - A Major Player in Vaccines Market II-59

Other Major Players Active in Vaccines Market II-59

Table 13: Vaccines Portfolio of GlaxoSmithKline and Merck:

Breakdown of Annual Sales (in US$ Million) for the year 2008

(includes corresponding Graph/Chart) II-60

Select Infectious Diseases and Vaccines II-60

Infectious Diseases II-60

Diphtheria II-60

Tetanus (Lockjaw) II-61

Pertussis (Whooping Cough) II-61

Vaccines for Diphtheria, Tetanus and Pertussis II-61

Select Diphtheria Vaccines by Company II-61

DTaP - A Combination Vaccine for Diphtheria, Tetanus and

Pertussis II-62

DT - A Combination Vaccine for Diphtheria and Tetanus II-62

Td - The Tetanus and Diphtheria Vaccine II-62

Tdap - A Vaccine for Tetanus, Diphtheria and Pertussis II-62

Measles II-62

Live, Attenuated (Freeze-Dried) Measles Vaccine II-63

Mumps II-63

MMR - A Combination Vaccine for Measles, Mumps and Rubella II-63

Side Effects of MMR Vaccine II-63

Polio & Vaccines II-64

Influenza Vaccines II-64

Hepatitis B Vaccine II-64

HPV Infection Vaccines II-65

HIV Vaccines - Research Clipped by Lack of Funds II-65

6. RESEARCH & DEVELOPMENT II-66

Emergent Begins Phase I/II Clinical Studies of AIG for Anthrax

Treatment II-66

Novartis Initiates Phase IIb Clinical Trials of Albuferon® II-66

Schering-Plough Concludes Phase III Trials for INTRON A® Plus

REBETOL™ Combination Therapy II-66

Progenics Advances Research on New Antibody Therapy for HIV II-67

Forest Labs Announces Encouraging Phase III Results of

Ceftaroline II-67

Pharmasset Completes Phase 1a Trial of PSI-7851, Initiates

Phase1b Study II-68

Roche Announces Positive Results of PEGASYS/ COPEGUS

Combination Therapy II-68

Novartis Announces Phase III Results of Menveo® Vaccine II-68

Discovery Laboratories Announces Pre-Clinical Results of

SURFAXIN® II-69

Emergent Commences Phase II Clinical Study of Typhoid Vaccine II-69

Enanta Begins Phase I Trial of EDP-322, the First MRSA-Active

Bicyclolide II-69

Roche, Pharmasset, InterMune Being Oral Anti-Virals Dual-

Combination Study II-70

ANRS, Pharmasset, Gilead Initiate Clevudine + Viread® Clinical

Trials II-70

7. PRODUCT LAUNCHES II-72

Rx Africa (Ethiopia) to Introduce Generic Pharmaceuticals II-72

Destiny Pharma Develops New Metallo-Porphyrin Anti-Bacterial Drug II-72

Galderma Laboratories Launches EpiduoTM Gel II-72

Ranbaxy Rolls Out Generic Valtrex II-72

Glenmark Introduces Onabet Topical Antifungal Cream II-73

MIT Scientists Develop a New Antibiotic, Rhodostreptomycin II-73

Watson Pharma Introduces Biaxin XL's Generic Version II-73

Taisho Toyama Pharmaceutical Rolls Out Zosyn® II-73

GSK Launches ALTARGO® in the UK II-74

Toyama Launches New Garenoxacin Quinolone Antibiotic II-74

Wockhardt to Introduce Cefprozil in the US II-74

MSD India Launches Invanza in India II-75

Macrolide Antibiotic Developed in the US II-75

University of Michigan Devises NMR Spectroscopy for Antibiotics II-75

Glycopeptide-Cephalosporin Antibiotics Developed in the US II-75

8. RECENT INDUSTRY ACTIVITY II-76

Merck Merges with Schering-Plough II-76

Beactica and Cubist Sign Agreement II-76

Akela Pharma Acquires Nventa Biopharmaceuticals II-76

GSK and Pfizer Establish New JV for Developing Anti-HIV Drugs II-76

Evotec and Cubist Ink Research Pact for Fragment-Based Drug

Discovery II-77

Grindeks Commences Production of Anti-flu Drug, Rimantadine-

Grindeks II-77

Galapagos Expands Partnership with GSK II-77

GSK Acquires Stiefel II-78

The Medicines Company Acquires Targanta II-78

Tibotec Signs Licensing and Partnership Deal with Gilead II-78

Abbott Buys Ibis Biosciences II-79

Elder and Strides on Expansion Mode II-79

Kemin Industries Acquires Amalyte Pharmaceuticals II-79

Valeant Pharmaceuticals International Acquires EMO-FARM II-79

Pfizer Inks Agreements with Claris Lifesciences and Aurobindo

Pharma II-80

moksha8 Extends Partnership with Roche II-80

Akorn Signs Agreement with Eli Lilly and Company II-80

Access Pharmaceuticals Acquires MacroChem II-80

Vertex Pharmaceuticals Acquires ViroChem Pharma II-81

sanofi-aventis Acquires Laboratorios Kendrick II-81

DSM Enters into Joint Venture with North China Pharmaceutical

Group II-81

NovaBay Inks Agreement with Medical University of Innsbruck II-82

Tibotec Collaborates with Global Alliance for TB Drug Development II-82

DSM Aired Plans to Divest DSM Deretil II-82

3i to Buy Alpharma Unit II-83

Three Rivers Acquires Infergen® HCV Drug From Valeant II-83

ULL Establishes New Antibiotics Unit in Himachal Pradesh II-83

Biocat to Expand Presence in the Indian Market II-83

Ranbaxy Signs Agreement with Merck II-84

Zydus Acquires Controlling Interest in Simayla Pharmaceuticals II-84

Novartis to Acquire Protez II-84

Marksans Acquires Relonchem II-85

Orchid Signs Licensing Agreement with Merck II-85

Forest and Novexel Sign Licensing Agreement II-85

Sanofi-aventis Collaborates with Novozymes II-85

Janssen-Cilag International Obtains Marketing Authorization

for INTELENCETM II-86

Nastech Pharmaceutical Company Changes Name to MDRNA II-86

Galderma Laboratories Acquires CollaGenex Pharmaceuticals II-86

Emergent BioSolutions Forges Joint Venture with the University

of Oxford II-87

Emergent BioSolutions to Acquire Recombinant Flu Vaccine,

FluBlok® II-87

AstraZeneca Acquires Arrow Therapeutics II-88

Cubist Submits INDs for CB-182,804 and CB-183,315 II-88

SRI International Partners with Blanca Pharmaceuticals to

Develop Antibiotics II-89

Allergan Acquires Esprit Pharma II-89

GSK And Anacor Team Up for Boron Chemistry-Based Antibiotics

and Antivirals II-89

J&J PRD Seeks FDA Approval for Doripenem Antibiotic II-90

J&JPRD Seeks FDA Approval for Ceftobiprole II-90

GSK to Cease Sale of Amprenavir Protease Inhibitor II-90

Iroko Bags Canadian Rights to Vancocin® II-91

AstraZeneca Purchases Biologics Production Facility from DSM

Biologics II-91

Depomed Expands Agreement with Watson Pharmaceuticals II-91

Depomed Terminates Agreement with Esprit Pharma II-91

Phylogica and Dynamic Microbials Inks Agreement II-91

Pharmasset Collaborates with University of Cincinnati II-92

Homeland Safety International Acquires Majority Stake in PLC

Marketing II-92

Ecopia and Caprion Merge to Form Thallion Pharmaceuticals II-92

9. DRUG APPROVALS II-93

FDA Clears Extended Therapy with INTRON A in Chronic HCV Patients II-93

Abbott Obtains EC Approval for Kaletra® in Treating HIV Patients II-93

Tibotec Gets EC Clearance for PREZISTA® in Treating HIV Patients II-93

Health Canada Approves Anti-HIV-1 Drug, ISENTRESS® II-93

Mylan Receives FDA Approval for Linezolid 600 mg Tablets II-94

Rottapharm/Madaus Obtains Clearance to Market ProQuin XR in

Sweden II-94

MiddleBrook Obtains NDA Approval for MOXATAG™ II-94

Tibotec Pharmaceuticals Obtains US FDA Approval for PREZISTA® II-94

Wyeth Receives an Approvable Letter from US FDA for TYGACIL® II-94

Astellas Pharma Receives Approval from US FDA for MYCAMINE® II-95

Cubist Pharmaceuticals Receives Health Canada Approval for

CUBICIN® II-95

Cubist Receives EC Approval for Extended Use of Cubicin® II-95

GSK Receives Approval for ALTARGO® in Europe II-96

Cubist Gains Approval for CUBICIN in Taiwan and South Korea II-96

10. FOCUS ON SELECT GLOBAL PLAYERS II-97

Abbott Laboratories (USA) II-97

Alcon Pharmaceuticals Ltd. (Switzerland) II-97

Astellas Pharma, Inc. (Japan) II-98

AstraZeneca PLC (UK) II-98

Bayer HealthCare AG (Germany) II-99

Bristol-Myers Squibb Co. (USA) II-99

Boehringer Ingelheim (Germany) II-100

Cubist Pharmaceuticals, Inc. (USA) II-100

Daiichi Sankyo Company, Limited (Japan) II-101

Eli Lilly and Company (USA) II-102

Gilead Sciences, Inc. (USA) II-102

GlaxoSmithKline Plc (UK) II-103

F. Hoffmann-La Roche, Ltd. (Switzerland) II-103

Johnson & Johnson (USA) II-104

Merck & Co., Inc (USA) II-104

Novartis AG (Switzerland) II-105

Pfizer, Inc. (USA) II-106

Sanofi-Aventis SA (France) II-106

Table 14: The below table exhibits worldwide vaccines sales

of the company for the year 2008: (includes corresponding

Graph/Chart) II-107

Wyeth Pharmaceuticals, Inc. (USA) II-108

11. GLOBAL MARKET PERSPECTIVE II-109

Anti-infectives by Region: II-109

Table 15: World Recent Past, Current & Future Analysis for

Anti-Infectives by Geographic Region - US, Japan, Europe, and

Rest of World Markets Independently Analyzed by Annual

Revenues in US$ Million for the Years 2006 through 2015

(includes corresponding Graph/Chart) II-109

Table 16: World 10-Year Perspective for Anti-Infectives by

Geographic Region - Percentage Breakdown of Dollar Revenues

for the US, Japan, Europe, and Rest of World Markets for 2006,

2009 & 2015 (includes corresponding Graph/Chart) II-110

Anti-Infectives by Therapeutic Class: II-111

Table 17: World Recent Past, Current & Future Analysis for

Anti-Infectives by Therapeutic Class - Antibacterials,

Antivirals, Antifungals, and Others* Markets Independently

Analyzed by Annual Revenues in US$ Million for the Years 2006

through 2015 (includes corresponding Graph/Chart) II-111

Table 18: World 10-Year Perspective for Anti-Infectives by

Therapeutic Class - Percentage Breakdown of Dollar Revenues

for Antibacterials, Antivirals, Antifungals, and Others*

Markets for 2006, 2009 & 2015 (includes corresponding

Graph/Chart) II-112

Anti-bacterials by Region: II-113

Table 19: World Recent Past, Current & Future Analysis for

Anti-Bacterials by Geographic Region - US, and Rest of World

Markets Independently Analyzed by Annual Sales Revenues in US$

Million for the Years 2006 through 2015 (includes

corresponding Graph/Chart) II-113

Table 20: World 10-Year Perspective for Anti-Bacterials by

Geographic Region - Percentage Breakdown of Annual Sales

Revenues for the US and Rest of World Markets for 2006, 2009 &

2015 II-113

Anti-bacterials By Drug-Class: II-114

Table 21: World Recent Past, Current & Future Analysis for

Anti-Bacterials by Drug Class - Cephalosporins, Penicillins,

Fluoroquinolones, Macrolides, and Others Markets Independently

Analyzed by Annual Sales Revenues in US$ Million for the Years

2006 through 2015 (includes corresponding Graph/Chart) II-114

Table 22: World 10-Year Perspective for Anti-Bacterials by

Drug Class - Percentage Breakdown of Annual Sales Revenues for

Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and

Others Markets for 2006, 2009 & 2015 (includes corresponding

Graph/Chart) II-115

Table 23: World Recent Past, Current & Future Analysis for

Cephalosporins by Geographic Region - US and Rest of World

Markets Independently Analyzed by Annual Sales Revenues in US$

Million for the Years 2006 through 2015 (includes

corresponding Graph/Chart) II-116

Table 24: World 10-Year Perspective for Cephalosporins by

Geographic Region - Percentage Breakdown of Annual Sales

Revenues for the US and Rest of World Markets for 2006, 2009 &

2015 II-116

Table 25: World Recent Past, Current & Future Analysis for

Penicillins by Geographic Region - US and Rest of World

Markets Independently Analyzed by Annual Sales Revenues in US$

Million for the Years 2006 through 2015 (includes

corresponding Graph/Chart) II-117

Table 26: World 10-Year Perspective for Penicillins by

Geographic Region - Percentage Breakdown of Annual Sales

Revenues for the US and Rest of World Markets for 2006, 2009 &

2015 II-117

Table 27: World Recent Past, Current & Future Analysis for

Fluoroquinolones by Geographic Region - US and Rest of World

Markets Independently Analyzed by Annual Sales Revenues in US$

Million for the Years 2006 through 2015 (includes

corresponding Graph/Chart) II-118

Table 28: World 10-Year Perspective for Fluoroquinolones by

Geographic Region - Percentage Breakdown of Annual Sales

Revenues for the US and Rest of World Markets for 2006, 2009 &

2015 II-118

Table 29: World Recent Past, Current & Future Analysis for

Macrolides by Geographic Region - US and Rest of World Markets

Independently Analyzed by Annual Sales Revenues in US$ Million

for the Years 2006 through 2015 (includes corresponding

Graph/Chart) II-119

Table 30: World 10-Year Perspective for Macrolides by

Geographic Region- Percentage Breakdown of Annual Sales

Revenues for the US and Rest of World Markets for 2006, 2009 &

2015 II-119

Table 31: World Recent Past, Current & Future Analysis for

Other Anti-bacterials by Geographic Region - US and Rest of

World Markets Independently Analyzed by Annual Sales Revenues

in US$ Million for the Years 2006 through 2015 (includes

corresponding Graph/Chart) II-120

Table 32: World 10-Year Perspective for Other Anti-bacterials

by Geographic Region - Percentage Breakdown of Dollar

Revenues for the US and Rest of World Markets for 2006, 2009

& 2015 II-120

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

HIV Market Perspective in the US III-1

HIV/AIDS - Prevalence III-1

Homosexual Males - A Significant Risk Group for HIV Infections III-2

Women - A High Risk Group for HIV/AIDS III-2

African-Americans - The Leading High Risk Ethnic Group for

HIV Infection III-2

Latinos - The Second Major Ethnic Risk Group for HIV Infection III-2

An Overview of Sexually Transmitted Diseases (STDs) III-3

Regulatory Environment III-3

Product Innovations/Introductions III-3

Strategic Corporate Developments III-5

FDA Regulations And Approvals III-11

Focus on Select Players III-13

B.Market Analytics III-21

Table 33: US Recent Past, Current & Future Analysis for

Anti-Infectives Market Analyzed with Annual Sales Revenues

in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) III-21

Table 34: US Recent Past, Current & Future Analysis for

Anti-Bacterials Market by Drug Class - Cephalosporins,

Penicillins, Fluoroquinolones, Macrolides, and Others

Markets Analyzed by Annual Sales Revenues in US$ Million for

Years 2006 through 2015 (includes corresponding Graph/Chart) III-22

Table 35: US 10-year Perspective for Anti-Bacterials Market

by Drug Class - Percentage Breakdown of Dollars Sales

Revenues for Cephalosporins, Penicillins, Fluoroquinolones,

Macrolides, and Others Markets for Years 2006, 2009 & 2015

(includes corresponding Graph/Chart) III-23

2. JAPAN III-24

A.Market Analysis III-24

Infectious Disease Market Witnessing Mixed Fortunes in Japan III-24

HIV Infection Prevalence - One of the Lowest Worldwide III-24

Hepatitis C Prevalence - Widespread and Driving the

Hepatitis C Drugs Market III-25

Table 36: Leading Hepatitis C Anti-viral Products in Japan

(2008(E)): Percentage Share Breakdown for PEG-Intron,

Pegasys, Intron A, Advaferon, Sumiferon, Feron, and Others

(includes corresponding Graph/Chart) III-25

Product Innovations/Introductions III-26

Focus on Select Players III-26

B.Market Analytics III-29

Table 37: Japanese Recent Past, Current & Future Analysis

for Anti-Infectives Market - Annual Revenues in US$ Million

for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-29

3. EUROPE III-30

A.Market Analysis III-30

Strategic Corporate Developments III-30

B.Market Analytics III-33

Table 38: European Recent Past, Current & Future Analysis

for Anti-Infectives Market by Geographic Region - France,

Germany, Italy, UK, Spain, and Rest of Europe Markets

Analyzed by Annual Sales Revenues in US$ Million for Years

2006 through 2015 (includes corresponding Graph/Chart) III-33

Table 39: European 10-year Perspective for Anti-Infectives

Market by Geographic Region - Percentage Breakdown of

Dollars Sales for France, Germany, Italy, UK, Spain, and

Rest of Europe Markets for Years 2006, 2009 & 2015 (includes

corresponding Graph/Chart) III-34

3a. FRANCE III-35

A.Market Analysis III-35

France - The Largest Market for Anti-Infectives in Europe III-35

Antibiotics Use Takes A Dip, As Regulatory Authorities'

Efforts Pays Off III-35

Strategic Corporate Development III-35

Focus on Select Players III-36

Sanofi-Aventis SA III-36

Table 40: The below table exhibits worldwide vaccines

sales of the company for the year 2008: (includes

corresponding Graph/Chart) III-37

B.Market Analytics III-37

Table 41: French Recent Past, Current & Future Analysis for

Anti-Infectives Market Analyzed with Annual Sales Revenues

in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) III-37

3b. GERMANY III-38

A.Market Analysis III-38

Strategic Corporate Development III-38

Focus on Select Players III-38

B.Market Analytics III-40

Table 42: German Recent Past, Current & Future Analysis for

Anti-Infectives Market Analyzed with Annual Sales Revenues

in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) III-40

3c. ITALY III-41

Market Analysis III-41

Table 43: Italian Recent Past, Current & Future Analysis for

Anti-Infectives Market Analyzed with Annual Sales Revenues

in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) III-41

3d. THE UNITED KINGDOM III-42

A.Market Analysis III-42

Infectious Diseases - A Quick Primer III-42

Table 44: Number of new Cases, and Deaths due to Infectious

Disorders in England (2006): Breakdown by Infection Type

(includes corresponding Graph/Chart) III-42

Research and Development of New Anti-Infectives III-43

Table 45: Number of New Anti-Infectives Approved in UK

(2003-2007): Breakdown by Therapeutic Class - Anti-Virals

and Anti-Bacterials III-43

Impediments to the Development of New Anti-infectives III-43

Scientific Barriers III-43

Economic Barriers III-44

Regulatory Barriers III-44

HIV/AIDS Prevalence - On the Rise III-44

Drug Resistant HIV Strains - Incidence Rising III-45

STD - Rising Incidence Poses Health Risks III-45

Product Innovations/Introductions III-45

Strategic Corporate Developments III-46

Focus on Select Players III-48

B.Market Analytics III-50

Table 46: UK Recent Past, Current & Future Analysis for

Anti-Infectives Market Analyzed with Annual Sales Revenues

in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) III-50

3e. SPAIN III-51

Market Analysis III-51

Table 47: Spanish Recent Past, Current & Future Analysis for

Anti-Infectives Market Analyzed with Annual Sales Revenues

in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) III-51

3f. REST OF EUROPE III-52

A.Market Analysis III-52

Focus on Select Market III-52

Russia - Leading the Prevalence of HIV/AIDS III-52

Acute Drug Supply Shortages Risk Lives HIV Victims III-52

Strategic Corporate Developments III-52

Focus on Select Players III-54

B.Market Analytics III-56

Table 48: Rest of Europe Recent Past, Current & Future

Analysis for Anti-Infectives Market Analyzed with Annual

Sales Revenues in US$ Million for Years 2006 through 2015

(includes corresponding Graph/Chart) III-56

4. REST OF WORLD III-57

A.Market Analysis III-57

Focus on Select Markets III-57

Canada III-57

HIV/AIDS Prevalence III-57

Asia-Pacific III-57

HIV/AIDS Prevalence III-57

HIV Infection Rising Among Male III-58

Australia III-58

HIV/AIDS Prevalence III-58

Chronic Hepatitis C Prevalence III-59

Bangladesh III-59

HIV/AIDS Prevalence III-59

Cambodia III-59

HIV/AIDS Prevalence III-59

China III-59

HIV/AIDS Prevalence III-59

Antibiotics Market III-60

Antibiotics Manufacturing III-60

Carbapenem Antibiotics Hold Great Potential III-60

China Represents a Major Market for Hepatitis B Therapies III-61

India III-61

HIV/AIDS Prevalence III-61

Not-for-Profit Organizations Active in HIV/AIDS Control

and Prevention III-61

AIDS Control Programs for Rural Youths in India III-62

Anti-Infectives Market Experiencing Double- Digit Growth III-62

Table 49: Pharmaceutical Market in India (2007):

Percentage Market Share Breakdown by Therapeutic Class

(includes corresponding Graph/Chart) III-63

Competition III-63

Top 5 Drug Producers in India, and their Major Products III-63

Injectable Antibiotics Demonstrate Robust Growth III-63

New Initiative to Develop Novel Antibiotic Molecules III-64

Major Players - Hepatitis B Vaccines III-64

Product Innovations/Introductions III-64

Strategic Corporate Developments III-65

Focus on Select Players III-69

B.Market Analytics III-70

Table 50: Rest of World Recent Past, Current & Future

Analysis for Anti-Infectives Market Analyzed with Annual

Sales Revenues in US$ Million for Years 2006 through 2015

(includes corresponding Graph/Chart) III-70

Table 51: Rest of World Recent Past, Current & Future

Analysis for Anti-Bacterials Market by Drug Class -

Cephalosporins, Penicillins, Fluoroquinolones, Macrolides,

and Others Markets Analyzed by Annual Sales Revenues in US$

Million for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-71

Table 52: Rest of World 10-year Perspective for

Anti-Bacterials Market by Drug Class - Percentage Breakdown

of Dollars Sales Revenues for Cephalosporins, Penicillins,

Fluoroquinolones, Macrolides, and Others Markets for Years

2006, 2009 & 2015 (includes corresponding Graph/Chart) III-72

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 77 (including Divisions/Subsidiaries - 85)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 54

Canada 1

Japan 3

Europe 16

France 2

Germany 3

The United Kingdom 3

Italy 1

Rest of Europe 7

Asia-Pacific (Excluding Japan) 10

Middle-East 1

------------------------------------------

To order this report:

Pharmaceutical Industry: Global Anti-Infectives Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker